Genelabs Biotechnology Financing

20 November 1995

Genelabs has finished the first phase of the financing for Genelabs Biotechnology Ltd, a joint venture with the government of Taiwan, for $14.6 million. In the initial phase, the Taiwanese Ministry of Finance is investing NT$153 million ($5.6 million) and Genelabs NT$131 million. GBL is focusing on late-stage development, manufacture and commercialization of newly-developed or formulated drugs, vaccines and other health care products for the Asian market. Genelabs president Irene Chow was expected to be appointed chairperson for the GBL board of directors as the Marketletter went to press.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight